Stock Detail

$ABBV

Healthcare · 8 tracked mentions in the last 90 days across 5 creators.

Valuation and creator stance reflect the last 90 days. The mention feed below shows the latest tracked mentions across all history.

Back to assets
Valuation Signal
UndervaluedDeveloping view
Creators are framing ABBV as undervalued.

ABBV leans undervalued across 3 creators and 4 classified valuation claims, with 3 direct claims carrying most of the signal.

Creator Stance
Moderate Buy · 60%
Based on 5 creator stances in the last 90 days.

Creator Evidence

Why creators say this

Valuation Filters
Investing Portfolio Pathway
Undervalued

Explicit claim • strong conviction • basis: fair value gap

I have a blended intrinsic value on ABBV of $275.90. They're currently trading below that value.

Basis: fair value gap
Let's Talk Money! with Joseph Hogue, CFA
Undervalued

Explicit claim • strong conviction • basis: multiple relative

and drug maker AbbVie ticker ABBV which trades for 18 times earnings even after it's 35% run.

Basis: multiple relative
Dividend Talks
Undervalued

Explicit claim • strong conviction • basis: fair value gap

And the next stock is where the ranking starts to become much more interesting because this is the first one where my valuation model shows a margin of safety above 20% and that is ABV.

Basis: fair value gap
Nathan Robert
Undervalued

Explicit claim • strong conviction • basis: price target upside

I really think this stock in the long run will give you 7 to 8% total return of your money back a year. If you look right now in the middle of my screen, no matter what you're getting 3.4% of your money back just in a qualified dividend every year, but I'm going to show you why I believe AbbVie will give you 3 to 4% stock price appreciation on top of this 3 and 1/2% dividend every single year on average.

Basis: price target upside

Mention History

Latest mentions across all history

Mention Filters

Feed

Loading mention history...